Development and validation of a deep neural network for predicting coronary heart disease in hypertensive patients using 24-hour ambulatory blood pressure monitoring: a retrospective study - Summary - MDSpire
Advertisement
Development and validation of a deep neural network for predicting coronary heart disease in hypertensive patients using 24-hour ambulatory blood pressure monitoring: a retrospective study
To develop and assess a deep learning model for predicting coronary heart disease (CHD) risk in hypertensive patients using 24-hour ambulatory blood pressure monitoring (ABPM) data.
Approach:
Study Design: A single-center retrospective cohort study involving 1,026 patients, with 718 for model development and 308 for internal validation.
Model Development: A deep neural network with three hidden layers was created and compared to eight conventional machine learning algorithms.
Feature Selection: Thirty-two clinical variables were evaluated, with a two-step feature selection process using the Boruta algorithm and LASSO regression.
Performance Evaluation: Model performance was assessed based on discrimination (AUC), calibration (Brier score), and clinical utility (decision curve analysis).
Interpretability: SHAP values were used to evaluate model interpretability.
Key Findings:
The deep neural network model achieved an AUC of 0.822 in the training cohort and 0.796 in the validation cohort.
The model had the lowest Brier score of 0.172, indicating superior calibration.
Nine predictors were identified as significant: diabetes mellitus, mean systolic blood pressure, time in target range of systolic blood pressure, left atrial diameter, left ventricular end-systolic diameter, left ventricular ejection fraction, use of antihypertensive medications, calcium channel blockers, and β-blockers.
Interpretation:
The deep neural network model enables identification of high-risk CHD patients with hypertension using routinely available clinical variables.
Limitations:
The study is limited to a single center, which may affect generalizability.
The model requires prospective multicenter external validation.
Conclusion:
The developed model requires further validation to assess its effectiveness in risk stratification for hypertensive patients at risk for CHD.